These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 15287683)

  • 1. [A new in star in antibiotic heaven--daptomycin].
    Holzgrabe U
    Pharm Unserer Zeit; 2004; 33(4):270. PubMed ID: 15287683
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin.
    Skiest DJ
    J Clin Microbiol; 2006 Feb; 44(2):655-6. PubMed ID: 16455939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin.
    Vikram HR; Havill NL; Koeth LM; Boyce JM
    J Clin Microbiol; 2005 Oct; 43(10):5384-7. PubMed ID: 16208025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daptomycin, a lipopeptide antibiotic in clinical practice.
    Weis F; Beiras-Fernandez A; Schelling G
    Curr Opin Investig Drugs; 2008 Aug; 9(8):879-84. PubMed ID: 18666036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The second life of daptomycin: analysis of a successful come-back].
    Decousser JW; Doucet Populaire F
    Med Mal Infect; 2008 Dec; 38 Spec No 2():1-3. PubMed ID: 19185200
    [No Abstract]   [Full Text] [Related]  

  • 6. The use of daptomycin for Staphylococcus aureus infections in critical care medicine.
    Alder J
    Crit Care Clin; 2008 Apr; 24(2):349-63, ix-x. PubMed ID: 18361950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin.
    French GL
    J Antimicrob Chemother; 2006 Dec; 58(6):1107-17. PubMed ID: 17040922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Who's winning the war?
    Gould IM
    J Antimicrob Chemother; 2008 Nov; 62 Suppl 3():iii3-6. PubMed ID: 18829723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Daptomycin. Reassessment of an antibiotic].
    Gobernado M
    Rev Esp Quimioter; 2007 Mar; 20(1):11-8. PubMed ID: 17530032
    [No Abstract]   [Full Text] [Related]  

  • 10. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections.
    Steenbergen JN; Alder J; Thorne GM; Tally FP
    J Antimicrob Chemother; 2005 Mar; 55(3):283-8. PubMed ID: 15705644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic challenges in the era of antibiotic resistance.
    Lee C
    Int J Antimicrob Agents; 2008 Dec; 32 Suppl 4():S197-9. PubMed ID: 19134519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan.
    Huang YT; Hsiao CH; Liao CH; Lee CW; Hsueh PR
    J Clin Microbiol; 2008 Mar; 46(3):1132-6. PubMed ID: 18199793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daptomycin: a rapidly bactericidal lipopeptide for the treatment of Gram-positive infections.
    Kanafani ZA; Corey GR
    Expert Rev Anti Infect Ther; 2007 Apr; 5(2):177-84. PubMed ID: 17402833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy.
    Lewis JS; Owens A; Cadena J; Sabol K; Patterson JE; Jorgensen JH
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1664-5. PubMed ID: 15793168
    [No Abstract]   [Full Text] [Related]  

  • 15. Diminished vancomycin and daptomycin susceptibility during prolonged bacteremia with methicillin-resistant Staphylococcus aureus.
    Bennett JW; Murray CK; Holmes RL; Patterson JE; Jorgensen JH
    Diagn Microbiol Infect Dis; 2008 Apr; 60(4):437-40. PubMed ID: 18096352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daptomycin: rationale and role in the management of skin and soft tissue infections.
    Seaton RA
    J Antimicrob Chemother; 2008 Nov; 62 Suppl 3():iii15-23. PubMed ID: 18829721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-clinical experience with daptomycin.
    Hawkey PM
    J Antimicrob Chemother; 2008 Nov; 62 Suppl 3():iii7-14. PubMed ID: 18829726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Daptomycin: revitalizing a former drug due to the need of new active agents against grampositive multiresistant bacterias].
    Hernández Martí V; Romá Sánchez E; Salavert Lletí M; Bosó Ribelles V; Poveda Andrés JL
    Rev Esp Quimioter; 2007 Sep; 20(3):261-76. PubMed ID: 18080024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daptomycin resistance in Enterococcus faecalis prosthetic valve endocarditis.
    Hidron AI; Schuetz AN; Nolte FS; Gould CV; Osborn MK
    J Antimicrob Chemother; 2008 Jun; 61(6):1394-6. PubMed ID: 18344547
    [No Abstract]   [Full Text] [Related]  

  • 20. Emergence of resistance to daptomycin during treatment of vancomycin-resistant Enterococcus faecalis infection.
    Munoz-Price LS; Lolans K; Quinn JP
    Clin Infect Dis; 2005 Aug; 41(4):565-6. PubMed ID: 16028170
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.